AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SymBio and Eisai to launch Symbenda (bendamustine hydrochloride) in Singapore for the treatment of low-grade non-Hodgkin's Lymphoma and chronic lymphatic leukaemia.
On 7 Sep 2010, SymBio Pharmaceuticals Ltd and Eisai Co Ltd announced that Eisai's Singapore subsidiary Eisai (Singapore) Pte Ltd launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia. Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive rights to develop and market the agent in Singapore and South Korea. A regulatory application seeking approval of bendamustine was submitted to the Singapore health authorities (Health Sciences Authority: HSA) by SymBio on 24 Dec 2008 and was …
-
- NATCO'S ANTI-CANCER DRUG CLOKERAN TO HIT MARKETS (drug is effective in the...
-
News wire article from: Asia Africa Intelligence Wire
July 29, 2004
700+ words
-
- Bendamustine launched in Singapore: SymBio, Eisai.
-
News wire article from: Chemical Business Newsbase
September 27, 2010
700+ words
-
- Genmab on schedule with research and development projects.
-
News wire article from: Chemical Business Newsbase
March 22, 2007
700+ words
-
- Fatal erythroderma associated with pentostatin.(Drug Points)(Statistical Data...
-
Magazine article from: British Medical Journal
August 28, 1999
700+ words
-
- Credit Suisse predicts peak sales of $2.2 bn for Genmab's Arzerra.
-
News wire article from: Chemical Business Newsbase
January 7, 2009
700+ words
